FIA
IOVA icon

FNY Investment Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

FNY Investment Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$1K – 797
2022
Q1 		$1K Buy
+100
New +$1.55K ﹤0.01% 670
2020
Q2 		– Sell
-155
Closed -$4K – 492
2020
Q1 		$4K Buy
+155
New +$4.11K ﹤0.01% 343

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
OIC
Orion Investment Company St. Louis, Missouri $343M AUM 52.59% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

FNY Investment Advisers's IOVA Position: Q2 2026 in Review

FNY Investment Advisers reduced its Iovance Biotherapeutics (IOVA) stake by 25% in Q2 2026, selling an estimated $7.6K and leaving 6,000 shares worth $24K. The position accounts for 0.01% of the portfolio, ranked #506.

FNY Investment Advisers first reported a position in IOVA in Q3 2020 and has held it in 8 quarters since. The position peaked at $1.07M in Q3 2020. 146 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • FNY Investment Advisers held 6,000 shares of Iovance Biotherapeutics worth $24K as of Q2 2026.
  • FNY Investment Advisers sold 2,000 Iovance Biotherapeutics shares in Q2 2026, an estimated $7.6K.
  • Iovance Biotherapeutics made up 0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #506 holding.
  • FNY Investment Advisers first reported a position in Iovance Biotherapeutics in Q3 2020 and has held it in 8 quarters since.
  • FNY Investment Advisers's Iovance Biotherapeutics position peaked at $1.07M in Q3 2020.
  • 146 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.